Filing Flows › Health Care › Allarity Therapeutics (ALLR)
Allarity Therapeutics (ALLR) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 15, 2026 · Allarity Therapeutics (ALLR) Q1 2026 earnings results →
Allarity Therapeutics made $25K in Q1 2026. Operating margin n/m, net loss $2.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 15, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $25K in Q1 2026.
Operating costs exceeded revenue by $2.7M, an operating margin of -10752.0%. The quarter ended with a net loss of $2.8M.
Operating cash flow was −$4.5M. Non-cash charges added back $160K of share-based compensation. Working capital and other items used $1.9M. Capital expenditures of $64K exceeded it, leaving free cash flow of −$4.6M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 15, 2026 | $25K | — | n/m | −$2.8M | −$4.5M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Allarity Therapeutics
We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic. Once defined, the DRP® gene expression signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity, and by extension, to identify those patients who may then be most likely to receive benefit from that specific anti-cancer therapeutic. We have developed and published DRP® signatures for dozens of anti-cancer therapeutics.
In its own words, from its 10-K, filed Mar 30, 2026.
Allarity Therapeutics against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ALLR Allarity Therapeutics | Q1 2026 | $25K | — | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Allarity Therapeutics 10-Q on SEC EDGAR · CIK 1860657 · Pharmaceutical Preparations
13F: who owns ALLR and who is buying
More on ALLR
History
Every quarter: Q1 2026 results